Omeros Corporation 2. Çeyrek 2026 Kazanç Görüşmesi Özeti

Omeros Corporation Q2 2026 Earnings Call Summary

Moby Intelligence

Thu, August 13, 2026 at 4:56 AM GMT+3 3 min read

• OMER +26.55%

Strategic Performance and Market Dynamics

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

• Yartemlia's first full quarter performance was driven by a significant shift toward adult transplant centers, which now represent approximately 75% of sales compared to initial pediatric-heavy utilization.

• Management is actively working to transition the clinical paradigm from treating TA-TMA as a 'diagnosis of exclusion' to proactive screening, which is expected to increase the identified patient population.

• The company achieved positive operational cash flow of $4.1 million, supported by strong net sales growth of 188% quarter-over-quarter and disciplined commercial execution.

• Strategic capital restructuring through share and note repurchases reduced the potential fully diluted share count by 5.8 million shares and eliminated $8.6 million in future interest payments.

• Market penetration is accelerating with 73 unique accounts ordering as of June 30, representing a 143% increase since the end of the first quarter.

• The launch strategy focuses on securing institutional access, with formulary approval already reached at approximately 55% to 60% of tracked top-tier U.S. transplant centers.

Growth Initiatives and Guidance Framework

• Management reaffirmed expectations to be company-wide cash flow positive by mid-2027, supported by current commercial momentum and the Novo Nordisk milestone structure.

• The company is pursuing a re-examination of the European marketing authorization for Yartemlia following a negative CHMP opinion, utilizing an independent expert group to review pivotal data.

• Pipeline expansion plans include initiating two investigator-sponsored studies by year-end for hyperinflammatory ARDS and prophylactic use in pediatric TA-TMA.

• Development of the MASP-2 platform continues with the finalization of Phase 2 indications for the long-acting antibody OMS1030 and candidate selection for the oral small molecule program.

• Revenue guidance remains withheld as management seeks more experience with prescribing trends, patient demand, and the impact of upcoming reimbursement milestones.

Regulatory and Financial Risk Factors

• A permanent J-code became effective July 1, and a New Technology Add-on Payment (NTAP) providing up to $287,000 in additional reimbursement is scheduled for October 1.

• The company recorded a $12.1 million non-cash mark-to-market gain on embedded derivatives, a volatile figure tied directly to fluctuations in the common stock price.

• A $1.9 million loss was recognized in connection with the June agreement to repurchase convertible notes, reflecting the difference between fair value and carrying amount.

• Management noted that while pediatric adoption was rapid, institutional inertia at large academic centers remains a challenge for shifting diagnostic standards.

Q&A Session Highlights

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Competitive dynamics regarding off-label C5 inhibitor use in TA-TMA

• Management does not view C5 inhibitors as direct competition because recent trials for ravulizumab missed their endpoints in both adult and pediatric settings.

• Continued off-label use of eculizumab is attributed to physician habit rather than clinical superiority, as Yartemlia targets the lectin pathway without compromising the adaptive immune response.

Inventory levels and potential for channel stuffing

• Management clarified that sales figures are 'pure' and do not include channel stocking, as the drug is delivered within 24 hours of order.

• Distributor inventory has remained consistent at approximately 1.5 weeks of supply since the first quarter launch.

Vial utilization differences between adult and pediatric patients

• Management noted they lack direct visibility into per-patient vial counts due to HIPAA, but ordering patterns are consistent across both demographics.

• Initial utilization may be higher per patient as centers currently treat the most severe cases, but vial requirements are expected to decrease as earlier diagnosis becomes standard.